Child, Critical Care, Drug Withdrawal Symptoms
Conditions
Brief summary
The study is a prospective interventional study with three main aims: 1. Describe the frequency and severity of withdrawal syndrome in a population of paediatric intensive care patients. 2. Test whether implementation of an algorithm for tapering of analgosedation changes the frequency and severity of withdrawal symptoms in the same population. 3. Investigate how the health care providers experience having to adhere to such an algorithm.
Detailed description
Patients \< 18 years of age treated in an intensive care unit for 5 days or more with infusion of opioids and/or benzodiazepines, are eligible for inclusion. Patients are included at the time tapering of these drugs is initiated. Part one of the study is observational. Drugs administered, complications, Comfort score and WAT-1 (Withdrawal Assessment Tool-1) score is recorded. Before part two of the study, an algorithm for tapering of analgosedation is implemented, and the data set is obtained as in part one. For part three of the study, focus group interviews will be used.
Interventions
OTHERAlgorithm for tapering og analgosedation
Algorithm for tapering og analgosedation
Sponsors
Oslo University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* \< 18 years * treated in PICU * Infusion of opioids and/or benzodiazepins for 5 days or more.
Exclusion criteria
* Neuromuscular disease * Cognitive/neurological disturbance caused by a disease * Multiple disabilities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean peak WAT-1 score | Through study completion, up to 21 days |
Secondary
| Measure | Time frame |
|---|---|
| Ventilator days | Through study completion, up to 21 days |
| ICU days | Through study completion, up to 21 days |
| Time used tapering analgosedation | Through study completion, up to 21 days |
| Adverse events | Through study completion, up to 21 days |
| Comfort score | Through study completion, up to 21 days |
| Drug doses used | Through study completion, up to 21 days |
Countries
Norway
Outcome results
None listed